drugset / Trial / NCT00289783

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

NCT00289783

Phase 3 Completed 4441 enrolled GlaxoSmithKline
RandomizedParallel-groupTriple-blindPrevention

Summary

This study evaluates the immunogenicity and consistency of 3 Hib-MenCY-TT vaccine lots and the safety and immunogenicity of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine, when each are co-administered with Pediarix® to healthy infants at 2, 4, and 6 months of age. The study will also evaluate the safety and immunogenicity of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine, when each are co-administered with M-M-R® II and Varivax® at 12 to 15 months of age.

Timeline

Start
2006-02-22
Primary completion
2007-08-27
Completion
2008-02-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator ActHIB Vaccine Intramuscular
Comparator HAEMOPHILUS INFLUENZAE TYPE B CAPSULAR POLYSACCHARIDE MENINGOCOCCAL OUTER MEMBRANE PROTEIN CONJUGATE ANTIGEN Vaccine Intramuscular
Subject Menhibrix Vaccine Intramuscular
Background M-M-R II Vaccine Subcutaneous
Background Pediarix Vaccine Intramuscular
Background Prevnar 13 Vaccine
Background Varivax Vaccine Subcutaneous